As I prepared for my women's group Christmas cookie exchange, I realized how tough this season might be for someone with celiac disease. This condition can cause immense damage to the intestines when susceptible individuals ...
Dec 9, 2023
0
0
For patients with high folate receptor α (FRα)-positive ovarian cancer, a first-in-class antibody-drug conjugate targeting FRα, mirvetuximab soravtansine-gynx (MIRV), shows a significant benefit over chemotherapy, according ...
Dec 7, 2023
0
0
Two studies led by researchers at The University of Texas MD Anderson Cancer Center demonstrated clinical benefit from novel targeted therapies, which may offer new treatment options for patients with metastatic hormone receptor-positive ...
Dec 6, 2023
0
1
In Argentina, perhaps the most psychoanalyzed country in the world, the rhetoric of psychology proved important in the push for a 2020 federal law that for the first time guaranteed free and safe access to abortion through ...
Dec 6, 2023
0
0
Published in The Lancet, results of the randomized phase III BEATcc academic trial (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030) show that adding immune checkpoint inhibitor atezolizumab to standard of care with bevacizumab and ...
Dec 4, 2023
0
0
Are you a gentle parent? If so, chances are good that, just like your children, you may need a nap.
Nov 30, 2023
0
1
The U.S. Food and Drug Administration has approved SpringWorks Therapeutics Inc.'s Ogsiveo (nirogacestat) tablets for adult patients with progressing desmoid tumors who require systemic treatment.
Nov 30, 2023
0
0
A new Phase Ib/II study from researchers at The University of Texas MD Anderson Cancer Center and Moffitt Cancer Center found that combining sensitizing drugs with a specific form of radiation therapy may be more effective ...
Nov 28, 2023
0
0
A recent study, published in Nature Communications, focuses on the interaction between free fatty acids (FFAs) and GPR84, a G protein-coupled receptor (GPCR).
Nov 22, 2023
0
0
After 40 years of treating metastatic bladder cancer with chemotherapy as a primary treatment, scientists now present a new approach using immunotherapy combinations. The results of two studies have been presented at the ...
Nov 16, 2023
0
1
